NOTIFICATION: This is a reminder, the comment period for all ISLB statement papers is now open email@example.com
Welcome to ISLB, INTERNATIONAL SOCIETY OF LIQUID BIOPSY
Founded in 2017 in the city of Granada, in Spain and with a global reach: by joining those professionals mainly oncology and specialties related to the use of liquid biopsies as a new clinical tool. We welcome, therefore, to the professionals of the liquid biopsy of the world. We want to be the link of all stakeholders in the LB theme, connecting professionals with diverse experience and experience and speaking with one voice for our discipline.
One of the aims of the ISLB is to create recommendations to develop reliable and sustainable diagnostics and prognostics tools using liquid biopsies which will benefit patient health management and their wellness.
JOIN ISLB TODAY!
The International Society of Liquid Biopsy (ISLB), is an international professional organization committed to the advancement of the Liquid Biopsy and the promotion of a multidisciplinary approach for the diagnosis and treatment of patients based on then use of liquid biopsies.
Joining ISLB is to join an international community of professionals in this discipline who share best practices and the latest knowledge in the use of Liquid Biopsy for the definitive implementation of this technology in the treatment and care of cancer and other diseases that could benefit from the use of Liquid Biopsy.
Liquid biopsies to monitor cancer
Being able to easily track cancer is vital in all stages of the disease. Doctors have long been able to monitor the disease with scans and by taking small tissue samples (biopsies), but now a new technique is becoming available to them: the liquid biopsy, which can deliver a lot of detailed information about a patient's tumour from a simple blood sample.
So how does it work? Inside a tumour, cells are growing at a high rate, but while many cancer cells are growing, some are also dying in a process called apoptosis. As dying cancer cells break up, they release fragments of their DNA. Some of that DNA can get into the blood stream, after which it's called circulating tumour DNA (or ctDNA). This circulating tumour DNA is ready for scientists to fish out with a simple blood sample.
Because of advances in DNA sequencing technology, doctors can pick up on these traces of DNA, and use them to track the mutations present in a cancer. Finding out this information helps doctors keep track of a patient's tumour and whether treatment is working, or find out early if a new scan or different treatment is needed.
Credit to: Cancer Research UK and Phospho Biomedical Animation